Intrinsic Value of S&P & Nasdaq Contact Us

Daxor Corporation DXR NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score
89/100
6/7 Pass
SharesGrow Intrinsic Value
$39.98
+326.2%
Analyst Price Target
$23.00
+145.2%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Daxor Corporation (DXR) trades at a trailing P/E of 5.2, forward P/E of 23.5. Trailing earnings yield is 19.28%, forward earnings yield 4.26%. PEG 0.21 (Peter Lynch undervalued ≤1.0). Graham Number is $19.23.

Criteria proven by this page:

  • VALUE (100/100, Pass) — P/E is below market average (5.2); PEG ≤ 1.0 — Peter Lynch undervalued (0.21); analyst target implies upside (+145.2%); earnings yield beats bond yields (19.28%).
  • PEG Ratio 0.21 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield 19.28% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
  • Analyst consensus target $23.00 (+145.2% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 89/100 with 6/7 criteria passed.

SharesGrow 7-Criteria Score
89/100
SG Score
View full scorecard →
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
FUTURE
100/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
MOAT
21/100
→ Income
GROWTH
100/100
→ Income
INCOME
100/100
→ Income

Valuation Snapshot — DXR

Valuation Multiples
P/E (TTM)5.2
Forward P/E23.5
PEG Ratio0.21
Forward PEG0.21
P/B Ratio1.04
P/S Ratio315.35
EV/EBITDA5.0
Per Share Data
EPS (TTM)$1.81
Forward EPS (Est.)$0.40
Book Value / Share$9.07
Revenue / Share$0.03
FCF / Share$0.03
Yields & Fair Value
Earnings Yield19.28%
Forward Earnings Yield4.26%
Dividend Yield0.00%
Graham Number$19.23
SharesGrow IV$39.98 (+326.2%)
Analyst Target$23.00 (+145.2%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 21.5 -0.19 2.04 17.06 0.36%
2017 -13.3 0.07 1.20 -16.33 0.68%
2018 -34.6 1.27 2.35 -33.41 0.37%
2019 -79.4 1.59 3.08 -342.23 -
2020 -28.8 -0.11 3.14 -17.53 -
2021 9.6 -0.03 2.15 -17.42 -
2022 15.2 -0.31 2.71 -222.48 -
2023 158.4 -1.76 1.31 1.29 -
2024 69.4 0.85 1.04 17.48 -
2025 8.0 0.01 1.60 146.07 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $0.33 $1.84M $1.46M 79.3%
2017 $-0.33 $-1.01M $-1.24M -
2018 $-0.24 $-918.45K $-885.78K -
2019 $-0.12 $-114.99K $-495.7K -
2020 $-0.43 $-996.3K $-1.71M -
2021 $1.18 $5.82M $4.75M 81.6%
2022 $0.60 $6.31M $5.18M 82.1%
2023 $0.06 $163.42K $280.64K 171.7%
2024 $0.11 $2.13M $536.33K 25.2%
2025 $1.84 $503.42K $9.17M 1821.5%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $0.08 $0.08 – $0.08 $2.28M $2.28M – $2.28M 1
2027 $0.15 $0.15 – $0.15 $2M $2M – $2M 1
2028 $0.40 $0.40 – $0.40 $14M $14M – $14M 1
2029 $1.00 $1.00 – $1.00 $29.16M $29.16M – $29.16M 1
2030 $1.80 $1.80 – $1.80 $50.27M $50.27M – $50.27M 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message